SCHEMBL19613862

SCHEMBL19613862

CCC(c1ccccc1Cl)N1CC[C@H](NC(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.42
KCNQ2 O43526 1/20 0.41
SCN1A P35498 1/20 0.40
SCN8A Q9UQD0 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 2/20 0.39
SSTR1 P30872 1/20 0.39
SSTR4 P31391 1/20 0.39
SIGMAR1 Q99720 2/20 0.39
P2RX7 Q99572 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MC4R P32245 1/20 0.39
CNR1 P21554 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613860 1.00 EPHX2 (0.42) EPHX2KCNQ2SCN1ASCN8AKDM4D
SCHEMBL19613859 1.00 EPHX2 (0.42) EPHX2KCNQ2SCN1ASCN8AKDM4D
SCHEMBL19627686 0.85 KDM4D (0.51) KDM4DKMT2AL3MBTL1
SCHEMBL19613515 0.84 MC4R (0.42) EPHX2KCNQ2SCN1ASCN8AMC4R
SCHEMBL19613179 0.84 OPRM1 (0.45) ALDH1A1MEN1KMT2AOPRM1OPRL1
SCHEMBL19613178 0.84 OPRM1 (0.45) ALDH1A1MEN1KMT2AOPRM1OPRL1
SCHEMBL19613987 0.84 OPRM1 (0.45) ALDH1A1MEN1KMT2AOPRM1OPRL1
SCHEMBL19613986 0.84 OPRM1 (0.45) ALDH1A1MEN1KMT2AOPRM1OPRL1
SCHEMBL19613514 0.84 MC4R (0.42) EPHX2KCNQ2SCN1ASCN8AMC4R
SCHEMBL19613180 0.84 OPRM1 (0.45) ALDH1A1MEN1KMT2AOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
EP-3458449-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2019-03-27 EP disclosed
WO-2017201468-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 WO disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B EPHX2 2484/4885KCNQ2 42/4885SCN1A 1/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B EPHX2 2484/4885KCNQ2 42/4885SCN1A 1/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B EPHX2 2484/4885KCNQ2 42/4885SCN1A 1/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B EPHX2 2242/4885KCNQ2 37/4885SCN1A 1/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B EPHX2 2484/4885KCNQ2 42/4885SCN1A 1/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B EPHX2 2242/4885KCNQ2 37/4885SCN1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.